In the Claims

B_1

2. (Amended) The pharmaceutical formulation according to claim 1, wherein the organic phase (i) has a solubilising capacity for the CCK antagonist in excess of 5mg per gram of organic phase.

21. (Amended) The pharmaceutical formulation according to Claim 1, wherein the organic phase comprises at least one oil selected from the group consisting of soya bean, safflower, sesame, rapeseed, peanut, olive, cotton seed and fish oils and mixtures thereof, alone or in combination with glycerine and/or a wax selected from full and/or partial triglycerides of fatty acids.

B_2

22. (Amended) The pharmaceutical formulation according to Claim 1 intended for intravenous use, wherein the hydrophilic phase is aqueous and has a viscosity of from 2500-7500cp at 20°C.

23. (Amended) The pharmaceutical formulation according to Claim 1 intended for use as a solid formulation, wherein the hydrophilic phase is gel forming, incorporates the opioid in the gel and forms a matrix incorporating the CCK antagonist and the glyceride derivative.

24. (Amended) The pharmaceutical formulation according to Claim 1, wherein the hydrophilic phase comprises a pharmacologically and pharmaceutically acceptable polymer or salt thereof selected from the group consisting of proteins, hyaluronic acid, alginic acids or salts thereof,

carboxymethylcellulose, methyl cellulose, other cellulose derivatives which are water-swellable, other water-swellable polymers, and water-soluble polymers.

25. (Amended) The pharmaceutical formulation according to Claim 1, wherein the carrier is in the form of an oil-in-water emulsion.

26. (Amended) The pharmaceutical formulation according to Claim 25, wherein the oil-in-water emulsion comprises

(i) an oil phase comprising a glyceride derivative; and

(ii) an aqueous phase optionally comprising a buffer whereby the emulsion has a pH of from 6.5 to 7.5 and optionally comprises an isotonicity regulator whereby the aqueous phase is made isotonic to blood plasma.

B2

27. (Amended) The pharmaceutical formulation according to Claim 25, wherein the average particle size of the emulsion is from 0.2 to 3.0μm.

28. (Amended) The pharmaceutical formulation according to claim 25 further comprising an emulsifying agent, a surfactant and/or a pH adjuster.

29. (Amended) The pharmaceutical formulation according to Claim 1, wherein the CCK antagonist is incorporated into the organic phase and the opioid is incorporated into the hydrophilic phase.

30. (Amended) The pharmaceutical formulation according to Claim 1, wherein the ratio of component (i) to component (ii) is within the range of 10:1 to 1:5 by weight.

31. (Amended) The pharmaceutical formulation according to Claim 1, wherein the ratio of component (a) to component (b) is within the range of 1:2 to 1:40 by weight.

32. (Amended) The pharmaceutical formulation according to Claim 1, wherein the CCK antagonist is selected from the group consisting of:

3S-(-)-(1,3-dihydro-3-(2-indolecarbonylamino)-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one;

3R-3-(N-(3-methylphenyl)ureido)-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one;

N-[1,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N-[3-(1,2,4-oxodiazol-5-one)phenyl]urea;

(-)-N-[2,3,-dihydro-5-(4,4-dimethylpiperidin-1-yl)-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-[indan-5-yl]urea; and

[N-[(3R)-5-(3-azabi-cyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea].

33. (Amended) The pharmaceutical formulation according to Claim 1, wherein the opioid is selected from the group consisting of morphine, codeine, or a salt thereof, and 14-hydroxymorphinan opioid analgesics and salts thereof.

34. (Amended) The pharmaceutical formulation according to Claim 1 in the form of a solid formulation, an injectable emulsion, a suppository, or a tablet.

35. (Amended) The pharmaceutical formulation according to Claim 1, in a unit dosage form suitable for the delivery of 0.5 to 300 mg per day of CCK antagonist to a patient in need thereof.

36. (Amended) The pharmaceutical formulation according to Claim 35, in unit dosage form suitable for oral use or use as a suppository for the delivery of 1 to 100mg per day of CCK antagonist to a patient in need thereof.

37. (Amended) The pharmaceutical formulation according to Claim 35 in unit dosage form suitable for intravenous use for the delivery of 1 to 300mg per day of CCK antagonist to a patient in need thereof.

39. (New) The pharmaceutical formulation according to Claim 24, wherein the protein is gelatine.

40. (New) The pharmaceutical formulation according to Claim 24, wherein the salt of alginic acid is sodium alginate.

41. (New) The pharmaceutical formulation according to Claim 24, wherein the carboxymethyl cellulose is cross-linked.

42. (New) The pharmaceutical formulation according to Claim 24, wherein the other cellulose derivatives which are water-swellable polymers are selected from the group consisting of hydroxypropylmethylcellulose and hydroxyethylcellulose.

43. (New) The pharmaceutical formulation according to Claim 24, wherein the other water-swellable polymer is polyvinylpyrrolidone (PVP).

44. (New) The pharmaceutical formulation according to Claim 24, wherein the water-soluble polymer is lactose.